Endologix, Inc. s trend and data analysis indicates that the stock price has dropped -1.81% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -44.84% . Looking at the past 52 week period, the stock price is down -17.23% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Endologix, Inc. has a negative value of -38.81 compared to overall market performance.Endologix, Inc. is having a Relative Strength Index of 60.34 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Endologix, Inc. (NASDAQ:ELGX) has climbed 6.73% in the past week and advanced 4.44% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 6.47% and the outperformance has advanced to 3.25% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. Endologix, Inc. (NASDAQ:ELGX) : On Friday heightened volatility was witnessed in Endologix, Inc. (NASDAQ:ELGX) which led to swings in the share price. The stock opened for trading at $6.78 and hit $7.1 on the upside , eventually ending the session at $7.06, with a gain of 3.22% or 0.22 points. The heightened volatility saw the trading volume jump to 1,649,079 shares. The 52-week high of the share price is $14.495 and the company has a market cap of $585 million. The 52-week low of the share price is at $4.78 .
Company has reported several Insider transactions to the SEC, on Dec 15, 2016, Iii Thomas F Zenty (director) purchased 3,000 shares at 6.51 per share price.On Dec 15, 2016, John D Mcdermott (CEO) purchased 10,000 shares at 6.67 per share price.On Dec 15, 2016, Vaseem Mahboob (CFO) purchased 20,000 shares at 6.25 per share price.
Endologix Last issued its quarterly earnings results on Feb 22, 2017. The company reported $-0.30 EPS for the quarter, missing the analyst consensus estimate by $ -0.12. Analyst had a consensus of $-0.18. The company had revenue of $47.46 million for the quarter, compared to analysts expectations of $48.81 million. The companys revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.08 EPS.
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.